NCT04439175View on ClinicalTrials.gov

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 25, 2016

Primary Completion Date

November 10, 2020

Study Completion Date

March 19, 2026

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma

Interventions

DRUG

Taselisib

Given PO

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH